Phase 3
N=130
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma
Refractory Multiple Myeloma · Stage II Multiple Myeloma · Stage III Multiple Myeloma
Bottom Line
View on ClinicalTrials.gov: NCT00217438 ↗Enrolled (actual)
130
Serious AEs
0.0%
Results posted
Sep 2014
Primary outcome: Primary: CR and Near CR Rates — 39; 22 percentage of participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- melphalan (Drug); amifostine trihydrate (Drug); peripheral blood stem cell transplantation (Procedure); fluorescence in situ hybridization (Genetic); bone marrow ablation with stem cell support (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Fred Hutchinson Cancer Center
- Primary completion
- Oct 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY CR and Near CR Rates |
39; 22 | — |
| SECONDARY Relative Toxicities Between Melphalan 280 mg/m^2 or Melphalan 200 mg/m^2 |
20; 10 | — |
Summary
RATIONALE: Giving chemotherapy drugs, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. Giving chemotherapy with a peripheral stem cell transplant once or twice, using stem cells from the patient or an identical brother or sister, may allow more chemotherapy to be given so more cancer cells are killed. Giving maintenance therapy after a stem cell transplant may kill any cancer cells that remain. It is not yet known which dose of melphalan is more effective in treating multiple myeloma (MM).
PURPOSE: This randomized phase III trial is studying two different doses of melphalan to compare how well they work when given together with amifostine followed by one or two autologous or syngeneic stem cell transplants and maintenance therapy in treating patients with stage II-III MM
Eligibility Criteria
Inclusion Criteria
- Patients who have MM undergoing autologous or syngeneic hematopoietic transplantation
- Patients must meet Salmon and Durie criteria for initial diagnosis of MM
- Transplant will be offered to patients with stage II or III MM
- Measurable disease, defined as serum monoclonal protein >= 0.2 g/dl or Bence Jones protein >= 200 mg/24 h
- Karnofsky >= 70 or Eastern Cooperative Oncology Group (ECOG) 0-2
- Life expectancy is not severely limited by concomitant illness
- Left ventricular ejection fraction >= 50%
- No uncontrolled arrhythmias or symptomatic cardiac disease
- Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and diffusion capacity of carbon monoxide (DLCO) >= 50%
- No symptomatic pulmonary disease
- Human immunodeficiency virus (HIV) negative
- Bilirubin = 60 cc/min, estimated or measured
- Signed informed consent
Exclusion Criteria
- Pregnant or lactating females
- Uncontrolled infection
- Planned tandem autologous/reduced intensity allograft
- Insufficient PBSC for an autologous transplant (< 3.0 x 10^6 CD34+ cells/kg total)
- Prior autologous transplant
- Non-secretory myeloma and patients who are in a complete response or near complete response after conventional therapy
- Patients unwilling to practice adequate forms of contraception if clinically indicated
- Male patients on study need to be consulted to use latex condoms, even if they have had a vasectomy, every time they have sex with a woman who is able to have children
- Patients with history of seizures
- Patients receiving antihypertensive therapy that cannot be stopped for 24 hours preceding amifostine treatment
Data sourced from ClinicalTrials.gov (NCT00217438). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.